Novo Nordisk A/S
HealthcareNYSE:NVO · New York Stock Exchange
+$0.33 today
Vol 10.16M · Avg 16.14M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$327.8B of revenue converted into $122.0B of net income for the selected period. Gross margin is 81.6% and net margin is 36.3%, showing how much revenue survives after costs and taxes. EPS is $27.41, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $309.1B +6.4% | $290.4B +25.0% | $232.3B +31.3% | $177.0B +25.7% | $140.8B | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $58.8B +32.0% | $44.5B +24.5% | $35.8B +25.7% | $28.4B +20.2% | $23.7B | $725.6M | $804.0M | $882.4M |
| Gross Profit | $250.3B +1.8% | $245.9B +25.1% | $196.5B +32.3% | $148.5B +26.8% | $117.1B | $8.9B | $7.6B | $6.2B |
| Gross Margin | 81.0% -3.7pp | 84.7% +0.1pp | 84.6% +0.7pp | 83.9% +0.7pp | 83.2% | 9.8% | 28.9% | 38.3% |
| Research & Development | $52.0B +8.3% | $48.1B +48.1% | $32.4B +34.9% | $24.0B +35.3% | $17.8B | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $70.3B +4.3% | $67.4B +9.4% | $61.6B +21.5% | $50.7B +23.4% | $41.1B | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $122.6B +4.3% | $117.5B +25.1% | $93.9B +27.4% | $73.7B +26.0% | $58.5B | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $22.0B +15.0% | $19.1B +103.0% | $9.4B +27.9% | $7.4B +22.2% | $6.0B | $374.2M | $1.2B | $631.8M |
| EBITDA | $156.7B +5.9% | $147.9B +29.1% | $114.6B +49.3% | $76.8B +17.4% | $65.4B | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 50.7% -0.2pp | 50.9% +1.6pp | 49.4% +6.0pp | 43.4% -3.0pp | 46.4% | 5.6% | 46.3% | 42.0% |
| Operating Income | $127.7B -0.5% | $128.3B +25.1% | $102.6B +37.1% | $74.8B +27.6% | $58.6B | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 41.3% -2.9pp | 44.2% +0.0pp | 44.2% +1.9pp | 42.3% +0.6pp | 41.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.3B -31.0% | $1.8B +71.9% | $1.1B +347.3% | $239.0M +3.5% | $231.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $4.2B +156.5% | $1.6B +202.6% | $542.0M +43.4% | $378.0M +30.8% | $289.0M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $2.9B +351.0% | -$1.1B -154.7% | $2.1B +136.5% | -$5.7B -1418.1% | $436.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $130.5B +2.6% | $127.2B +21.5% | $104.7B +51.6% | $69.1B +16.9% | $59.1B | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 42.2% -1.6pp | 43.8% -1.3pp | 45.1% +6.0pp | 39.0% -2.9pp | 42.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $28.1B +7.3% | $26.2B +24.8% | $21.0B +55.1% | $13.5B +19.6% | $11.3B | $1.3B | -$1.6B | $745.2M |
| Net Income | $102.4B +1.4% | $101.0B +20.7% | $83.7B +50.7% | $55.5B +16.3% | $47.8B | $4.9B | $4.8B | $4.7B |
| Net Margin | 33.1% -1.6pp | 34.8% -1.3pp | 36.0% +4.7pp | 31.4% -2.5pp | 33.9% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $23 +1.7% | $23 +21.4% | $19 +52.3% | $12 +17.9% | $10 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $23 +1.8% | $23 +21.5% | $19 +52.4% | $12 +17.8% | $10 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $4.4B -0.1% | $4.5B -0.6% | $4.5B -1.1% | $4.5B -1.4% | $4.6B | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $4.4B -0.3% | $4.5B -0.7% | $4.5B -1.1% | $4.5B -1.3% | $4.6B | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Merck & Co., Inc.
NYSE:MRK
$296.18B
Novartis AG
NYSE:NVS
$292.74B
AstraZeneca PLC
NYSE:AZN
$278.85B
Amgen Inc.
NASDAQ:AMGN
$190.79B
Thermo Fisher Scientific Inc.
NYSE:TMO
$174.66B
Gilead Sciences, Inc.
NASDAQ:GILD
$155.57B
Abbott Laboratories
NYSE:ABT
$152.81B
Pfizer Inc.
NYSE:PFE
$149.27B
GSK plc
NYSE:GSK
$106.58B
Sanofi
NASDAQ:SNY
$106.52B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does NVO generate?
Novo Nordisk A/S (NVO) reported $309.06B of revenue in fiscal 2025.
Is NVO profitable?
Novo Nordisk A/S (NVO) reported $102.43B of net income, with a net margin of 33.1%.
Explore More
Continue the stock analysis
Jump to another research area for this company.